X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (406) 406
hematology (300) 300
male (280) 280
oncology (276) 276
female (274) 274
middle aged (249) 249
adult (235) 235
index medicus (207) 207
aged (188) 188
antineoplastic combined chemotherapy protocols - therapeutic use (128) 128
treatment outcome (126) 126
chemotherapy (121) 121
non-hodgkins-lymphoma (96) 96
rituximab (95) 95
disease-free survival (94) 94
prognosis (88) 88
lymphomas (85) 85
aged, 80 and over (83) 83
therapy (79) 79
lymphoma (74) 74
retrospective studies (67) 67
adolescent (66) 66
classification (66) 66
antineoplastic agents - therapeutic use (64) 64
neoplasm staging (64) 64
remission induction (63) 63
recurrence (62) 62
cancer (60) 60
lymphoma, non-hodgkin - drug therapy (57) 57
survival analysis (55) 55
hemic and lymphatic diseases (52) 52
follicular lymphoma (50) 50
combined modality therapy (49) 49
disease (48) 48
follow-up studies (48) 48
phase-ii (48) 48
care and treatment (47) 47
cyclophosphamide - administration & dosage (47) 47
vincristine - administration & dosage (46) 46
b-cell lymphoma (44) 44
fludarabine (44) 44
antineoplastic combined chemotherapy protocols - administration & dosage (43) 43
prednisone - administration & dosage (43) 43
survival (41) 41
vidarabine - analogs & derivatives (41) 41
doxorubicin - administration & dosage (39) 39
transplantation (39) 39
chronic lymphocytic-leukemia (38) 38
survival rate (38) 38
trial (37) 37
young adult (37) 37
hematology, oncology and palliative medicine (36) 36
patients (35) 35
antineoplastic combined chemotherapy protocols - adverse effects (34) 34
bleomycin - administration & dosage (33) 33
brentuximab vedotin (33) 33
cyclophosphamide (33) 33
radiotherapy (33) 33
antineoplastic agents - adverse effects (31) 31
hodgkin disease - drug therapy (31) 31
immune system diseases (31) 31
analysis (30) 30
salvage therapy (30) 30
hodgkin's disease (29) 29
phase-ii trial (29) 29
positron-emission-tomography (29) 29
abridged index medicus (28) 28
drug administration schedule (28) 28
high-dose chemotherapy (28) 28
lymphoma, large b-cell, diffuse - drug therapy (28) 28
hodgkin disease - pathology (27) 27
macop-b (27) 27
response criteria (27) 27
lymphoma, non-hodgkin - pathology (26) 26
radioimmunotherapy (26) 26
time factors (25) 25
vidarabine - administration & dosage (25) 25
antineoplastic agents (24) 24
combination chemotherapy (24) 24
fdg-pet (24) 24
follow-up (24) 24
antineoplastic agents - administration & dosage (23) 23
bone-marrow transplantation (23) 23
italy (23) 23
lymphoma, large b-cell, diffuse - pathology (23) 23
lymphoma, non-hodgkin - therapy (23) 23
malignant-lymphoma (23) 23
research (23) 23
t cells (23) 23
antibodies, monoclonal - therapeutic use (22) 22
chop (22) 22
immunohistochemistry (22) 22
large-cell lymphoma (22) 22
methotrexate - administration & dosage (22) 22
non-hodgkin's lymphomas (22) 22
non-hodgkins-lymphomas (22) 22
prednisone (22) 22
prospective studies (22) 22
t-cell lymphoma (22) 22
cancer research (21) 21
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Leukemia, ISSN 0887-6924, 2014, Volume 28, Issue 8, pp. 1687 - 1697
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9747, pp. 1164 - 1174
Summary Background On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal... 
Internal Medicine | CYTOKINE-RELEASE | MEDICINE, GENERAL & INTERNAL | PLUS CYCLOPHOSPHAMIDE | CHEMOIMMUNOTHERAPY | PROGRESSION-FREE SURVIVAL | INITIAL THERAPY | LYMPHOMA | STEM-CELL TRANSPLANTATION | EXPRESSION | III TRIAL | DELETION | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Incidence | Leukopenia - chemically induced | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Severity of Illness Index | Antibodies, Monoclonal, Murine-Derived | Drug Administration Schedule | Immunologic Factors - administration & dosage | Kaplan-Meier Estimate | Rituximab | Treatment Outcome | Vidarabine - analogs & derivatives | Disease Progression | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Vidarabine - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Chronic lymphocytic leukemia | Cyclophosphamide | Fludarabine | Patient outcomes | Dosage and administration | Research | Drug therapy | Studies | Clinical trials | Mutation | Medical statistics | Epidemiology | Annual meetings | Teaching hospitals
Journal Article
Blood, ISSN 0006-4971, 12/2017, Volume 130, Issue 25, pp. 2691 - 2692
In this issue of Blood, Pro et al have reported that it is possible to cure a subset of patients with relapsed or refractory (R/R) systemic anaplastic large... 
HODGKIN | BRENTUXIMAB VEDOTIN SGN-35 | EXPERIENCE | LARGE-CELL LYMPHOMA | HEMATOLOGY | NAMED PATIENT PROGRAM
Journal Article
Journal Article
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10094, pp. 555 - 566
Journal Article
Journal Article
HEMATOLOGICAL ONCOLOGY, ISSN 0278-0232, 12/2017, Volume 35, Issue 4, pp. 909 - 910
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2008, Volume 26, Issue 32, pp. 5156 - 5164
Journal Article